Related Experiment Video
Updated: Oct 8, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Arborinine suppresses ovarian cancer development through inhibition of LSD1
Nan Li1, Liang Yang2, Hongling Zuo1
1Department of Gynecology, the Second Hospital of Hebei Medical University, No.215 Heping West Road, Shijiazhuang 050000, Hebei, China.
Aims:
Epithelial ovarian carcinoma is the most lethal female reproductive malignancy in the world. Paclitaxel and carboplatin are generally the first-line treatment drugs for ovarian cancer patients, but numerous patients may develop chemotherapy resistance. Thus, it is urgent to identify novel drugs for ovarian cancer treatment. Arborinine has been known as a broad-spectrum anti-tumor agent due to it possesses a potent cytotoxic effect on various cancer cells.
Materials And Methods:
This study aimed to evaluate its anti-tumor effect and the potential underlying mechanism on ovarian cancer cell line SKOV3. The effect of arborinine on SKOV3 cell proliferation and movement were evaluated by MTT assay and cell migration and invasion assays, respectively. The RT-qPCR and Western Blot assays were employed to determine target gene expression. The tumor-bearing mouse model was applied to assess the anti-tumor effect of arborinine in vivo.
Key Findings:
Our results demonstrated that arborinine treatment significantly inhibited the cell proliferation and tumor growth of SKOV3 in a dose-dependent manner. Arborinine treatment dose-dependently reduced LSD1 expression, resulting in increased H3K4m1 expression. Importantly, arborinine also potently suppressed cell migration and invasion of SKOV3 via reducing epithelial-mesenchymal transition (EMT) of SKOV3.
Significance:
Arborinine may serve as a potential drug candidate for developing new strategies for ovarian cancer treatment.
Insights
Arborinine shows promise as a novel ovarian cancer treatment by inhibiting cancer cell growth and spread. This natural compound effectively reduces tumor growth and metastasis in preclinical models.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Epithelial ovarian carcinoma is a leading cause of cancer death in women worldwide.
- Current treatments like paclitaxel and carboplatin face challenges due to chemotherapy resistance.
- Novel therapeutic agents are urgently needed for effective ovarian cancer treatment.
Purpose of the Study:
- To investigate the anti-tumor effects of arborinine on the SKOV3 ovarian cancer cell line.
- To elucidate the underlying molecular mechanisms of arborinine's action.
- To evaluate arborinine's efficacy in a preclinical in vivo model.
Main Methods:
- MTT assays for cell proliferation.
- Cell migration and invasion assays.
- RT-qPCR and Western Blot for gene expression analysis.
- In vivo tumor-bearing mouse model.
Main Results:
- Arborinine significantly inhibited SKOV3 cell proliferation and tumor growth in a dose-dependent manner.
- Arborinine reduced Lysine-Specific Demethylase 1 (LSD1) expression, increasing H3K4me1.
- Arborinine suppressed cell migration and invasion by reducing epithelial-mesenchymal transition (EMT).
Conclusions:
- Arborinine demonstrates potent anti-tumor activity against ovarian cancer.
- The compound targets LSD1 and EMT pathways, offering a novel therapeutic mechanism.
- Arborinine holds potential as a candidate for new ovarian cancer treatment strategies.
More Related Videos
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
